piomat
Posted by piomat
August 30, 2021
August 30, 2021

Tumor-derived GDF-15 to suppress T-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.

Joerg Wischhusen, Markus Haake, Neha Vashist, Sabrina Genßler, Kilian Wistuba-Hamprecht, Patrick Harter,...

Read More
piomat
Posted by piomat
August 30, 2021
August 30, 2021

Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation

Jui-Hsia Weng, Peter David Koch, Harding H. Luan, Ho-Chou Tu, Kenichi Shimada,...

Read More
piomat
Posted by piomat
August 30, 2021
August 30, 2021

GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma

Zhaowei Wang, Lei He, Weina Li, Chuanyang Xu, Jieyu Zhang, Desheng Wang,...

Read More
piomat
Posted by piomat
August 30, 2021
August 30, 2021

Tumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment

Markus Haake, Neha Vashist, Sabrina Genssler, Kristin H. Eichler, Birgitt Fischer, Jessica...

Read More
piomat
Posted by piomat
May 20, 2021
May 20, 2021

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...

Read More
piomat
Posted by piomat
May 19, 2021
May 19, 2021

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...

Read More
piomat
Posted by piomat
May 4, 2021
May 4, 2021

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...

Read More
piomat
Posted by piomat
March 1, 2021
March 1, 2021

CatalYm Announces Key Management and Board Changes

CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...

Read More
piomat
Posted by piomat
January 28, 2021
January 28, 2021

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...

Read More
piomat
Posted by piomat
November 10, 2020
November 10, 2020

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...

Read More
WordPress Cookie Notice by Real Cookie Banner